top of page
line5_edited.jpg

spsMOSAICS

Conditions

image.png
  • All prices are in Euro (€), and exclusive of 21% value added tax (VAT)

  • Single-user trial licenses are only available for Windows builds

  • All other licenses are available for Windows, UNIX/LINUX and MacOS platforms

  • Collaborator licenses are available to partners in formal research collaborations with Saddle Point Science Europe BV, of which results are to be published under joint authorship

  • Students enrolled at degree-awarding institutions can purchase single-user licenses only, proof of student status (e.g. copy of a university ID card) will be required

  • Support includes:

    • one-to-one installation

    • demonstration/introduction (on-site or remotely)

    • software support

    • results interpretation (remotely)

  • Software manuals are made available as electronic (PDF) documents

  • SaddlePoint DatasetManager included in all packages (Free of charge)

line5.jpg

Features
per user

License type
Duration
Support
Manual
Multi-core
Trial
2 months
Student
1 year
Collaborator
1 year
Public sector
1 year
Commercial
1 year

Costs
per user

License type
Duration
1 user
2 users
Additional users
Trial
2 months
free
Student
1 year
€ 1.100,00
Collaborator
1 year
€ 7.800,00
€ 11.700,00
€2.600,00 each
Public sector
1 year
€ 14.500,00
€ 21.750,00
€4.380,00 each
Commercial
1 year
€ 19.600,00
€ 29.400,00
€6.530,00 each

Publications in which the pipeline was used

  • Häggström, C., Rowley, M., Liedberg, F., Coolen, A. C. C., & Holmberg, L. (2023). Latent heterogeneity of muscle‐invasive bladder cancer in patient characteristics and survival: A population‐based nation‐wide study in the Bladder Cancer Data Base Sweden (BladderBaSe). Cancer Medicine, 12(12), 13856–13864. https://doi.org/10.1002/cam4.5981

  • Barber, P. R., Weitsman, G., Lawler, K., Barrett, J. E., Rowley, M., Rodríguez-Justo, M., Fisher, D. J., Gao, F., Tullis, I. D. C., Deng, J., Brown, L., Kaplan, R., Hochhauser, D., Adams, R., Maughan, T., Vojnovic, B., Coolen, A. C. C., & Ng, T. (2019). HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. JNCI: Journal Of The National Cancer Institute, 112(9), 944–954. https://doi.org/10.1093/jnci/djz231

  • ​Häggström, C., Van Hemelrijck, M., Garmo, H., Robinson, D., Stattin, P., Rowley, M., Coolen, A. C. C., & Holmberg, L. (2018). Heterogeneity in risk of prostate cancer: A Swedish population‐based cohort study of competing risks and Type 2 diabetes mellitus. International Journal Of Cancer, 143(8), 1868–1875. https://doi.org/10.1002/ijc.31587

  • ​Rowley, M., Garmo, H., Van Hemelrijck, M., Wulaningsih, W., Grundmark, B., Zethelius, B., Hammar, N., Walldius, G., Inoue, M., Holmberg, L., & Coolen, A. C. C. (2017). A latent class model for competing risks. Statistics in Medicine, 36(13), 2100–2119. https://doi.org/10.1002/sim.7246

  • Wulaningsih, W., Vahdaninia, M., Rowley, M., Holmberg, L., Garmo, H., Malmström, H., Lambe, M., Hammar, N., Walldius, G., Jungner, I., Coolen, A. C. C., & Van Hemelrijck, M. (2015). Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer, 15(1). https://doi.org/10.1186/s12885-015-1928-z

line5.jpg

Interested in purchasing a licence or starting a free trial?

We are grateful for your interest.
Thank you!

lines3_edited.jpg
bottom of page